Regeneron Q4 revenues $3.43B (+1% YoY); Dupixent up 31%; full-year guidance issued

REGENERON PHARMACEUTICALS, INC.

2023-FY EPS reported $34.77 revenue$13,117,200,000

Q4 GAAP EPS $10.19, non-GAAP $11.86; FY GAAP EPS $34.77, non-GAAP $43.79.
Dupixent global net sales Q4 $3.22B (+31% YoY), FY $11.59B (+33%). EYLEA franchise U.S. net sales down 2% in Q4.
Pipeline: Dupixent COPD sBLA and linvoseltamab BLA submitted; EYLEA HD approved in EU/Japan.
FY2024 guidance: GAAP R&D $4.82-5.07B, SG&A $2.89-3.09B, gross margin 86-88%.
Share repurchases $2.215B in FY2023; $1.5B remain. CFO Robert Landry to retire.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REGENERON PHARMACEUTICALS, INC. reported the quarter and year ended December 31, 2023 results: revenue $3.43 billion (Q4 2023), $13.12 billion (Full year 2023), net income $1,160 million (Q4 2023 GAAP), $3,954 million (Full year 2023 GAAP), EPS $10.19 per diluted share (Q4 2023 GAAP), $34.77 per diluted share (Full year 2023 GAAP).

Period: the quarter and year ended December 31, 2023
Revenue: $3.43 billion (Q4 2023), $13.12 billion (Full year 2023)
Net income: $1,160 million (Q4 2023 GAAP), $3,954 million (Full year 2023 GAAP)
EPS: $10.19 per diluted share (Q4 2023 GAAP), $34.77 per diluted share (Full year 2023 GAAP)
Result: reported results

Exact text from the filing

On February 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001804220-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.